TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven intermediate or high grade B-cell non-Hodgkin's lymphoma (other than Burkitt's, non-Burkitt's, undifferentiated, or lymphoblastic lymphoma) B-cell non-Hodgkin's lymphoma positive for CD19 and/or CD20 by slide-based immunohistochemistry or flow cytometry No mantle cell or follicular lymphoma Measurable disease, defined by at least one of the following: Physical examination Radiographic findings of at least 2 dimensions Bidimensional measurable defect or mass measuring at least 2 cm in diameter on radionuclide or CT scan Enlarged spleen extending at least 2 cm below the costal margin provided that there is no other likely explanation besides lymphomatous involvement Enlarged liver extending at least 5 cm below the costal margin along with biopsy-proven lymphomatous hepatic involvement No history of transformed lymphoma No known posttransplantation lymphoproliferative disorder No CNS involvement CALGB patients 60-65 years of age must not be eligible for any other study of higher priority A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS: Age: See Disease Characteristics 60 and over Performance status: ECOG 0-3 Life expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 (unless due to lymphoma) Platelet count greater than 100,000/mm3 (unless due to lymphoma) Hepatic: Bilirubin no greater than 3.0 mg/dL Renal: Creatinine less than 2.1 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No active heart disease including congestive heart failure, myocardial infarction within the past 3 months, or symptomatic ventricular arrhythmia LVEF at least 45% if prior history of heart disease exists Other: HIV negative No other malignancy within the past 5 years except squamous cell or basal cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior biologic response modifier therapy No prior immunotherapy No prior rituximab Chemotherapy: No prior cytotoxic chemotherapy No concurrent dexrazoxane Endocrine therapy: Prior corticosteroids allowed Radiotherapy: No prior radiotherapy No prior radioimmunotherapy Surgery: Not specified

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with refractory or relapse acute myeloid leukemia not in remission after 2 cycles of induction chemotherapy early relapse (1st remission less than 6 months) not in remission after 1 cycle of re-induction chemotherapy multiple relapse~* age 16-60 years~* with inform consent~* no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage~* HLA matched related (6/6) or unrelated donors (at least 8/10)~Exclusion Criteria:~* age less than 18 years or over 61 years~* liver function/renal function damage (over 2 X upper normal range)~* with mental disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- intensive chemo - RIC preparation (Type: EXPERIMENTAL): The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent before initiation of any study related procedures~2. Male or non-pregnant female aged 18 to ≤ 75 years~3. Referred for PCI or structural cardiac intervention and planned to receive bivalirudin treatment~4. Only subjects in whom the treating physician feels that clopidogrel and prasugrel are equivalent on the basis of available clinical literature will be included.~Exclusion Criteria:~1. Currently receiving glycoprotein IIb/IIIa inhibitors.~2. Have received prasugrel or clopidogrel within 2 weeks~3. Serum creatinine level \>2.0~4. Hypersensitivity to bivalirudin, prasugrel, clopidogrel or aspirin~5. Currently on heparin administration or administered ≤ 4.5 h prior to intervention~6. Thrombocytopenia (\<50,000/µL)~7. Severe systemic hypertension defined as systolic blood pressure \>180 mm Hg and/or diastolic blood pressure \>110 mm Hg~8. Body weight \< 60 kg~9. Cardiogenic shock~10. Acute pericarditis~11. Active internal bleeding~12. History of bleeding diathesis within previous thirty days~13. Any history of intracranial hemorrhage, Transient ischemic attack (TIA ) or stroke~14. Arteriovenous malformations or aneurysms~15. Major surgical procedures or severe physical trauma within last thirty days.~16. Symptoms or findings suggestive of aortic dissection~17. Pregnancy~18. Participation in other clinical research studies involving the evaluation of investigational drugs or devices within 30 days of enrollment~19. Incompetent subjects or subjects otherwise unable to provide informed consent~20. Subjects in whom the treating physician believes that one agent (prasugrel or clopidogrel) is preferable over the other will be excluded from study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: ACTIVE_COMPARATOR): Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Intraoperative Nausea and Vomiting During Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking ASA I-II non-laboring women with single gestations ≥36 weeks~* Scheduled or unscheduled cesarean delivery under spinal anesthesia~* Height: 5 feet-5 feet 11 in.~Exclusion Criteria:~* Laboring women needing an emergency cesarean delivery~  * Subjects less than 18 years of age~ * Receipt of a drug with antiemetic properties in the 24 hours prior to cesarean section~ * Allergy to ondansetron, or metoclopramide~ * Severe hypertensive disease of pregnancy defined as systolic blood pressure (SBP)\>160mmHg, diastolic blood pressure (DBP)\>110mmHg requiring antihypertensive treatment or associated with significant proteinuria.~ * Severe Cardiac disease in pregnancy with marked functional limitations~ * Diabetes type I~ * Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants~ * Morbid obesity (body mass index (BMI)\>45)~ * Inclusion in another anesthetic study involving drug administration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Metoclopramide (Type: ACTIVE_COMPARATOR): Prophylaxis with metoclopramide and phenylephrine infusion.
- Phenylephrine infusion (Type: PLACEBO_COMPARATOR): Prophylactic phenylephrine infusion and placebo antiemetics
- Combination Group (Type: ACTIVE_COMPARATOR): Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adults healthy volunteers and adult patients with anterior uveitis who wish to participate.~Exclusion Criteria:~* Patients with anterior uveitis who have other systemic diseases/conditions not related to their anterior uveitis, like high blood pressure, diabetes or epilepsy.~* Patients with ocular comorbidity or compliactions to their anterior uveitis, such as elevated ocular pressure or glaucoma.~* Previous or current macular edema or other posterior segment complications related to uveitis.~* Subjects with visual acuity worse than 0.8~* Subjects/patients with cataracts or other ocular media opacities~* Subjects/patients who are allergic to local anesthesia or mydriatics.~* Subjects/patients with high myopia/hyperopia~* Subjects/patients who have had intraocular surgery, although previous uncomplicated LASIK correction for low-grade myopia were accepted.~* Subjects/patients who cooperate poorly.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diclofenac (Type: EXPERIMENTAL): Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
- Dexamethasone (Type: EXPERIMENTAL): Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Evaluation of a CONSORT Based Online Writing Tool

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Adults~* Masters or doctoral students~Exclusion criteria~* not in the field of medical research~* not adults~* no masters or doctoral level education

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Online writing tool (Type: EXPERIMENTAL): Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
- writing with no specific support. (Type: OTHER): The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cilostazol Augmentation Study in Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men/women over sixty years old~* Patients with slight and moderate dementia (MMSE score is over 10 under 26.)~* Patients with probable Alzheimer's disease according to the standard of NINCDS-ADRDA~* Patients accompanied with WMHI on Brain MRI (Fazeka's scale 1\~3)~Exclusion Criteria:~* Those who do not agree to the test in a written form~* Patients who accompany other diseases except cerebral atrophy or change of subcortical white matter due to Alzheimer's disease on brain MRI~* Patients who should not use Cilostazol (① patients with bleeding tendency ② patients with congestive heart failure ③ patients who have a medical history of hypersensitivity to this medicine or constituent of this medicine ④ those who use anticoagulant and clot buster)~* Patients who suffer from nerve diseases or mental diseases which have influence on cognitive function except Alzheimer's disease (for example, schizophrenia, severe depression, mental retardation and etc.)~* Patients who are suspected to have a personal history of drug addiction or alcoholism within recent 10 years~* Patients who have severe problems in eye sight or hearing so that it is impossible to conduct the test smoothly~* Patients who the researchers think are inappropriate for taking part in the test

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cilostazol (Type: EXPERIMENTAL): Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group means dementia patients group receiving donepezil with placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be ≥ 18 years of age~* Patients with histologically diagnosed relapsed high grade serous ovarian cancer (including primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease \>6 months (\>/=183 days) after completion of their last platinum therapy.~* Documented germline mutation in Breast Cancer susceptibility genes: BRCA1 and/or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)~* At least one lesion that can be accurately assessed at baseline by CT/MRI and is suitable for repeated assessment.~* Patients must have received at least 2 prior platinum based lines of chemotherapy - Patients must be partially platinum sensitive or platinum sensitive~* Patients must be suitable to start treatment with single agent chemotherapy based on physician's choice~* Patients must have normal organ and bone marrow function measured within 28 days of randomisation,~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Patients must have a life expectancy ≥ 16 weeks~* Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing.~Exclusion Criteria:~* BRCA 1 and/or BRCA2 mutations that are considered to be non detrimental~* Exposure to any investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation~* Any previous treatment with a Polyadenosine 5'diphosphoribose polymerisation (PARP) inhibitor, including olaparib.~* Patients who have platinum resistant or refractory disease~* Patients receiving any systemic chemotherapy within 3 weeks prior to first dose of study treatment~* Previous single agent exposure to the selected chemotherapy regimen for randomisation. - Prior malignancy in the last 5 years, unless curatively treated and recurrence free (few exceptions apply).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1/OLAPARIB (Type: EXPERIMENTAL): olaparib 300mg oral tablets; twice daily
- 2/CHEMOTHERAPY (Type: ACTIVE_COMPARATOR): Physician's choice single agent chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* In general good health~* Female participants have a negative pregnancy test just prior to vaccination on Day 1~Exclusion Criteria:~* History of Hepatitis B Infection or vaccination~* Known or suspected hypersensitivity to any component of Recombivax HB™ vaccine (e.g., aluminum, yeast)~* Administration of hepatitis B immune globulin, serum immune globulin, or any other blood-derived product within 3 months prior to vaccination on Day 1~* Receipt of an inactivated virus vaccine within 14 days or a live virus vaccine within 30 days prior to vaccination on Day 1~* Participation on prior study using an investigational drug or vaccine in prior 3 months~* Known or suspected impairment of immunologic function or recent use of immunomodulatory medications, excluding topical or inhaled steroids~* Pregnant or nursing women or women planning to become pregnant within the study period

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- V232 Modified Process Hepatitis B Vaccine: Lot A (Type: EXPERIMENTAL): Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
- V232 Modified Process Hepatitis B Vaccine: Lot B (Type: EXPERIMENTAL): Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
- V232 Modified Process Hepatitis B Vaccine: Lot C (Type: EXPERIMENTAL): Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
- V232 Current Process Hepatitis B Vaccine (Type: ACTIVE_COMPARATOR): Recombivax HB™ (Hepatitis B Vaccine \[Recombinant\]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Up-Down Oxytocin Infusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-emergent cesarean delivery with planned spinal anesthesia (i.e. elective planned cesarean delivery for malposition, patient choice, cervical pelvic disproportion, previous cesarean delivery and other diagnosis that require a predetermined cesarean delivery)~2. American Society of Anesthesia physical status class I \& II (ASA I - Healthy, ASA II - mild and controlled systemic disease, eg. controlled essential hypertension)~3. Age ≥ 18 years~4. Term gestational age (≥ 37 weeks)~5. English-speaking~Exclusion Criteria:~1. Morbid Obesity (Body Mass Index ≥ 45 kg/m2) (Morbidly obese parturients require a dose of local anesthetic less than the standardized dose in this study and the blood pressure cuff occasionally needs to be replaced by an intraarterial catheter due to limitations in size)~2. Laboring women~3. Urgent or emergency cesarean delivery~4. Severe hypertensive disease of pregnancy defined as systolic blood pressure (SBP) \> 160mmHg, diastolic blood pressure (DBP) \> 110mmHg and/or requiring antihypertensive treatment or associated with significant proteinuria~5. Severe maternal cardiac disease~6. Subjects predisposed to uterine atony and postpartum hemorrhage (i.e. placenta previa, multiple gestation, macrosomia, polyhydramnios, uterine abnormalities, or bleeding diathesis, \> 2 previous CD)~7. Fetal anomalies /Intrauterine Fetal Demise~8. Failed spinal anesthesia~9. Patient enrollment in another study involving a study medication within 30 days of CD~10. Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* breast cancer with measurable locally recurrent or metastatic lesions;~* candidate for chemotherapy;~* HER2-positive disease;~* ECOG PS of \<=2.~Exclusion Criteria:~* previous anticancer therapy for metastatic breast cancer;~* previous radiotherapy for metastatic breast cancer (except for adjuvant radiotherapy \>=6 months before enrollment);~* chronic daily treatment with corticosteroids (\>=10mg/day), aspirin (\>325 mg/day) or clopidogrel (\>75mg/day);~* other primary tumor within last 5 years, except for adequately treated cervical cancer in situ, squamous or basal cell skin cancer;~* uncontrolled hypertension or significant cardiovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete